Drug Trial Radar · NCT04936178
A Study of NB003 in Patients With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
258
Actual
Start
Aug 6, 2021
Primary completion
Aug 1, 2025
Study completion Aug 1, 2025
Sponsor
- Lead sponsor
- Ningbo Newbay Technology Development Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies
Conditions
- Advanced Solid Tumor
Interventions
NB003 tabletsDrug
NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicitiesTime frame: Approximately 24 months since the escalation first subject enrolled
- Incidence of adverse eventsTime frame: Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled
- Objective Response Rate (ORR)Time frame: Approximately 26 months since the Expansion first subject enrolled
- Duration of Response(DOR)Time frame: Approximately 26 months since the Expansion first subject enrolled.
Locations
32 sites in 6 countries. Site status is shown where the registry gives one.
Standford University
Stanford, California
Mayo Clinic
Jacksonville, Florida
Dana-Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center
Long Island City, New York
Oregon Health & Science University (OHSU)
Portland, Oregon
U T MD Anderson Cancer Center Investigational Pharmacy Services
Houston, Texas
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guandong, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guandong, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Xiangya Hospital, Central South University
Changsha, Huanan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
The Second Affiliated Hospital of Xi'An Jiaotong University
Xi'an, Shaanxi, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Zhejiang University school of medicine
Hangzhou, Zhejiang, China
Centre Léon Bérard
Lyon, Rhone, France
Institut Gustave Roussy
Villejuif, Val de Marne, France
Asan Medical Center
Seoul, Seoul, South Korea
Samsung Medical Center
Seoul, Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Madrid, Spain
Royal Marsden Hospital-London
London, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.